BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29297949)

  • 1. Effect of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on Akt protein expression is more effective in head and neck cancer cell lineages that retain PTEN protein expression.
    Pontes FSC; Pontes HAR; de Souza LL; de Jesus AS; Joaquim AMC; Miyahara LAN; Fonseca FP; Pinto Junior DS
    J Oral Pathol Med; 2018 Mar; 47(3):253-259. PubMed ID: 29297949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines.
    Shintani S; Zhang T; Aslam A; Sebastian K; Yoshimura T; Hamakawa H
    Int J Oncol; 2006 Nov; 29(5):1111-7. PubMed ID: 17016641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
    Ui T; Morishima K; Saito S; Sakuma Y; Fujii H; Hosoya Y; Ishikawa S; Aburatani H; Fukayama M; Niki T; Yasuda Y
    Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy.
    Yin X; Zhang H; Lundgren K; Wilson L; Burrows F; Shores CG
    Int J Cancer; 2010 Mar; 126(5):1216-25. PubMed ID: 19662650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X; Zhang H; Burrows F; Zhang L; Shores CG
    Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
    Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
    Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H; Zhang T; Chen R; McConkey DJ; Ward JF; Curley SA
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
    Sauvageot CM; Weatherbee JL; Kesari S; Winters SE; Barnes J; Dellagatta J; Ramakrishna NR; Stiles CD; Kung AL; Kieran MW; Wen PY
    Neuro Oncol; 2009 Apr; 11(2):109-21. PubMed ID: 18682579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.
    Sain N; Krishnan B; Ormerod MG; De Rienzo A; Liu WM; Kaye SB; Workman P; Jackman AL
    Mol Cancer Ther; 2006 May; 5(5):1197-208. PubMed ID: 16731752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17-Allylamino-17-Demethoxygeldanamycin and the Enhancement of PS-341-Induced Lung Cancer Cell Death by Blocking the NF-κB and PI3K/Akt Pathways.
    Lee KH; Jang AH; Yoo CG
    Am J Respir Cell Mol Biol; 2015 Sep; 53(3):412-21. PubMed ID: 25633180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma.
    Duus J; Bahar HI; Venkataraman G; Ozpuyan F; Izban KF; Al-Masri H; Maududi T; Toor A; Alkan S
    Leuk Lymphoma; 2006 Jul; 47(7):1369-78. PubMed ID: 16923571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17-(Allylamino)-17-Demethoxygeldanamycin Enhances Etoposide-Induced Cytotoxicity via the Downregulation of Xeroderma Pigmentosum Complementation Group C Expression in Human Lung Squamous Cell Carcinoma Cells.
    Chen JC; Ma PF; Lin YC; Wu CH; Peng YS; Zheng HY; Lin MC; Li YT; Lin YW
    Pharmacology; 2018; 102(1-2):91-104. PubMed ID: 29953987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents.
    Cohen SM; Mukerji R; Samadi AK; Zhang X; Zhao H; Blagg BS; Cohen MS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3(Suppl 3):S483-90. PubMed ID: 21837531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells.
    Cervantes-Gomez F; Nimmanapalli R; Gandhi V
    J Pharmacol Exp Ther; 2011 Nov; 339(2):545-54. PubMed ID: 21821695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA aneuploidy-specific therapy for head and neck squamous cell carcinoma.
    García Martínez J; García-Inclán C; Suárez C; Llorente JL; Hermsen MA
    Head Neck; 2015 Jun; 37(6):884-8. PubMed ID: 24623685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck.
    Pickhard A; Gröber S; Haug AK; Piontek G; Wirth M; Straßen U; Rudelius M; Reiter R
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Jun; 117(6):733-42. PubMed ID: 24726415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.